TGTX as reported
TG Therapeutics, Inc. reported $800M of revenue over the trailing twelve months, +76% on the year before. 11 reported series are charted on this page, each one as filed.
$800M
Revenue, trailing twelve months · to Q2 2026 · +76% against the twelve months before
- Net Income
- $441M
Net Income · +630% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $17M
Free Cash Flow · −129% year on year · trailing twelve months to Q2 2026
- Op Margin
- 18%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $800M | +76% | Q2 2026 |
| Net Income | $441M | +630% | Q2 2026 |
| EPS | $2.75 | +643% | Q2 2026 |
| Gross Margin | 82% | n/a | Q2 2026 |
| Op Margin | 18% | n/a | Q2 2026 |
| Net Margin | 67% | n/a | Q2 2026 |
| ROE | 74% | n/a | Q2 2026 |
| ROA | 36% | n/a | Q2 2026 |
| ROIC | 13% | n/a | Q2 2026 |
| Free Cash Flow | $17M | −129% | Q2 2026 |
| P/E | 20.0 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
TG Therapeutics, Inc. (TGTX) - Revenue & ProfitRevenue & ProfitTG Therapeutics, Inc. (TGTX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com